35 results about "Precursor substance" patented technology

The invention relates to the technical field of biology, in particular to an inducer, a reagent combination and application of the inducer in preparation of anisodamine. The inducing agent comprises silver nitrate, acetylsalicylic acid and methyl jasmonate, the components of the inducing agent cooperate with one another, compatibility is high, synergistic interaction can be achieved, and the efficiency of the inducing agent for rapidly converting hyoscyamine into anisodamine is further improved. According to the invention, a suspension cell culture technology is adopted, and an optimized callus culture medium, a precursor substance hyoscyamine and an inducer are combined, so that compared with an initial material anisodamine tanguticum used by an existing anisodamine hydrobromide raw material medicine, the anisodamine hydrobromide raw material medicine has the advantages of short growth cycle, stable content and components, environmental protection and no damage to natural resources; the invention provides a new approach for obtaining a starting material for the production of an anisodamine hydrobromide bulk drug, and is suitable for popularization and application.

The invention relates to a preparation method of a platinum-doped hollow gold nanorod with high photo-thermal stability. The invention belongs to the technical field of nano material preparation. The preparation method comprises the following steps: adding a tellurium precursor substance and a selenium precursor substance into a hydrazine hydrate-containing solution, continuously magnetically stirring, and diluting by using an aqueous solution of lauryl sodium sulfate after the reaction is completed, so as to obtain the tellurium-selenium nanorod; and dispersing the prepared tellurium-selenium nanorod in pure water, adding a gold precursor, a platinum precursor and a modifier at the same time, and then performing centrifugal separation to obtain the platinum-doped hollow gold nanorod. The thermal stability of the hollow gold nanorod is effectively improved through platinum doping, and when the platinum doping proportion is 10% or above, the light and heat stability of the hollow gold nanorod is obviously improved; the positive significance is realized on the full play of the effect of the material in photo-thermal therapy and related combined therapy application.

The invention discloses an ergothioneine-producing recombinant engineering bacterium as well as a construction method and application thereof, and belongs to the technical field of gene recombination fermentation. The method comprises the following steps: by taking escherichia coli as a starting bacterium, carrying out recombinant expression on a histidine trimethyl inner salt cysteine sulfoxide synthetase egt1 gene, an L-histidine methyltransferase egtD gene, a histidine trimethyl inner salt cysteine sulfoxide lyase egt2 gene, a methionine adenosine transferase metK gene, an adenylate kinase adK gene and an adenine phosphoribose transferase apt gene; on this basis, supply of precursor substances including histidine, cysteine and methionine is further improved through metabolic transformation, the yield of the finally obtained recombinant engineering bacterium for producing ergothioneine reaches 2.54 g / L after 48 h of shake-flask culture, the yield of a 5L fermentation tank reaches 18 g / L after further enlarged culture, the yield of ergothioneine is guaranteed while energy consumption and cost are reduced, and the method is suitable for industrial production. The method is suitable for practical popularization.

The present application provides a method for preparing a liposome composition. In the method, a containing step is provided, including: providing precursor liposomes wrapping a platinum drug precursor; and culturing the precursor liposomes in a salt solution to convert the platinum drug precursor into a platinum drug to obtain the liposome composition. The precursor liposomes are obtained by the following steps: hydrating the platinum drug to obtain the platinum drug precursor; and adding the platinum drug precursor to a lipid bilayer carrier to obtain the precursor liposomes. The liposome composition prepared by the method has better coating rate and stronger drug loading capacity.

The invention relates to the field of erbium complexes, in particular to a preparation method and application of a metal erbium complex. The chemical formula of the metal erbium complex is (C5H6N) [Er (tfac) 4], and tfac-is deprotonated 1, 1, 1-trifluoroacetylacetone. The metal erbium complex is prepared through solvent volatilization and slow diffusion and a low-temperature crystallization method, namely, an absolute ethyl alcohol solution of erbium chloride, 1, 1, 1-trifluoroacetylacetone and pyridine are added into a three-necked bottle according to the molar ratio of 1: 4: 1, then absolute ethyl alcohol is added, and heating and stirring are conducted; cooling to room temperature, collecting pink and transparent blocky crystals, washing with absolute ethyl alcohol, and drying in vacuum. The metal erbium complex has a remarkable quenching effect on bovine serum albumin in an ethanol solution, and can be used as a drug precursor; the bacteriostasis rate on escherichia coli is 93.36%, and the compound can be used as a bacteriostatic agent.

The present invention discloses a class of compounds having an aromatic amide structure and their applications. The structural formula of the compound is shown below: #imgabs0# The present invention uses in vitro anti-tumor cell experiments as a carrier to evaluate the efficacy of the compound in treating various cancers. It is found that the compound has good in vitro activity and extremely high selectivity, and can be used as a precursor substance for further development to exert cancer treatment effects by selectively inhibiting aldehyde-keto reductase 1C3.

The invention discloses an AKR1C3 selectively activated small molecule drug conjugate and application of the AKR1C3 selectively activated small molecule drug conjugate. The invention discloses a series of compounds with a structure as shown in a general formula I, and also discloses application of the compounds in cancer treatment. The inventor evaluates the efficacy of the compound represented by the general formula I in treatment of various cancers by taking an in-vitro anti-tumor cell experiment as a carrier, and finds that the compound has good in-vitro activity and extremely high selectivity and can be used as a precursor substance for further development of a cancer treatment effect through selective activation of aldoketoreductase 1C3.

The present disclosure relates to the technical field of biotechnology, in particular to carbonyl reductase mutant and its application. Specifically, the present disclosure provides a carbonyl reductase mutant for catalyzing the preparation of (R)-8-chloro-6-hydroxyoctanoic acid ethyl ester from 8-chloro-6-oxooctanoic acid ethyl ester. The mutant protein is a non natural protein and undergoes mutations in three core amino acids related to enzyme catalytic activity in the initial carbonyl reductase. The advantageous effect of the present disclosure is that the carbonyl reductase mutant provided by the present disclosure has the characteristic of efficiently catalyzing the preparation of the precursor substance (R)-8-chloro-6-hydroxyoctanoic acid from 8-chloro-6-oxooctanoic acid ethyl ester, and can efficiently catalyze the oxidation-reduction reaction of 8-chloro-6-oxooctanoic acid, with a product space-time yield of 99.9 g·L−1·h−1 or more.

The utility model relates to a building block type 18F-FDG synthesis module device which comprises a base module, a valve group module and a reagent group module, and the base module is a first building block type module used for installing a reaction tube and providing positioning for the valve group module; the valve group module is a second building block type module which integrates a plurality of control valves, pipelines, QMA columns and solid-phase extraction columns required by 18F-FDG synthesis, and the second building block type module is directly arranged at the mounting position of the first building block type module; the reagent group module is a third building block type module which integrates a plurality of injectors for storing prodrugs and reagents required by the synthesis process and a product purification column, and the third building block type module is directly inserted into the second building block type module. According to the utility model, one 18F-FDG synthesis unit can be formed by simply splicing and combining the three building block type modules, so that the preparation work of 18F-FDG synthesis can be quickly completed, and a plurality of independently running 18F-FDG synthesis units can be placed in one protection box through the combination of a plurality of building block type bases.

An injection device for injecting a drug into a patient is disclosed. The injection device comprises a housing, a first substance chamber configured to receive a first precursor of the drug, and a second substance chamber configured to receive a second precursor of the drug. The injection device also includes a user activatable mechanism configured to open a first fluid path between the first and second substance chambers and permit mixing of the first and second precursor substances to form the drug when activated, and a needle connectable in fluid communication with the drug through a second fluid path. The user activatable mechanism is further configured to open the second fluid path when activated and thereby permit injection of the drug through the needle.

The invention relates to the technical field of chemical biological medicines, in particular to a preparation method and application of metal oxide hybrid hollow polydopamine microspheres. PSS is used as a hard template, metal ions and dopamine are adsorbed through static electricity, non-adsorbed metal ions are removed through dialysis, then the metal ions are oxidized into metal oxides through hydrothermal treatment, meanwhile, dopamine is subjected to self-polymerization to form polydopamine, and the composite material with the PSS as a core and the PDA as a shell is formed. A polydopamine-based core-shell structure with uniform size and controllable morphology of metal oxide particles is embedded, a hollow structure is formed along with etching of PSS and metal oxide, and a hollow structure with a nano plug is formed along with secondary coordination nucleation of metal ions after drug loading; due to the existence of the metal oxide, the stability of the adjustable structure of the prodrug is enhanced; the huge cavity structure is beneficial for increasing the drug loading capacity and the packaging efficiency of the anti-tumor small molecule drug; the composite material can realize directional delivery and efficient release of drugs.

The invention belongs to a mass spectrum technology, and particularly provides a sewage poison condition tracing method which comprises the following steps: A1, designing a tracing scheme according to poison condition abnormity of sewage sampling nodes, and the scheme comprises sampling nodes of sewage convergence countercurrent upward hierarchy; a2, collecting and analyzing the concentrations of drug protomers and metabolites thereof of raw water samples of all sampling nodes of the previous layer of the sampling nodes with abnormal toxicity conditions, and identifying the sampling nodes with abnormal toxicity conditions of the layer; circulating to the last-stage sampling node; a3, analyzing the sewage collection condition in the last-stage sampling node, and screening out a minimum building unit of a suspected poison source; and A4, entering the minimum building unit, collecting evidences, and determining the drug-related personnel. The method has the advantages of accurate and rapid tracing and the like.

The application belongs to the technical field of homogeneous catalysis, and discloses application of a ten-core 3d-4f supramolecular nanocage material in catalyzing a three-component Strecker reaction. The ten-core 3d-4f supramolecular nanocage material is used as a nanoreactor to realize synthesis of a biologically active drug precursor through the three-component Strecker reaction. The method has simple operation steps and can realize industrialized preparation. The prepared ten-core 3d-4f supramolecular nanocage material has high catalytic activity, catalytic stability and catalytic efficiency in catalyzing the three-component Strecker reaction.

Disclosed are a method for biological total synthesis of paclitaxel key precursor substance baccatin III, a biological material and use thereof. The bioenzyme composition used in the method comprises a taxane 9α-hydroxylase (T9αH) and a taxane C4-C20 oxetanase (TOT). According to the disclosure, a core component of a baccatin III biosynthetic pathway is identified, a baccatin III artificial synthesis route is constructed, thereby paving the way for efficiently developing a green low-carbon production pathway of taxane products (such as paclitaxel) through synthetic biology.

The invention discloses a temperature control method and system for preparing bilirubin, and the method comprises the steps: obtaining a precursor substance of bilirubin, the precursor substance being biliverdin; dissolving the biliverdin in a physiological buffer solution to form a uniform solution; placing the uniform solution in a temperature control reactor, and carrying out heating pretreatment for a first stage duration so as to ensure that a precursor substance is completely dissolved and a primary reaction is started; the temperature of the temperature control reactor is subjected to dynamic temperature progressive loading of the intermediate reaction for the second stage duration, so that biliverdin is partially converted into bilirubin; and carrying out uniform temperature transition of the third-stage duration on the temperature in the temperature control reactor, cooling the solution to room temperature after the reaction is finished so as to terminate the reaction, carrying out centrifugal separation on the obtained product, and collecting the supernate, thereby obtaining the bilirubin solution. By utilizing the embodiment of the invention, efficient conversion from biliverdin to bilirubin can be realized through accurate multi-stage temperature control, and high-purity bilirubin is obtained.

The application discloses a Saccharomyces cerevisiae de novo synthesis of naringenin engineering strain and a construction method and application thereof, and the engineering strain is constructed by modifying a genome of the Saccharomyces cerevisiae CEN.PK2-1C as follows: substrate competition pathway genes are knocked out, anti-feedback inhibition genes are overexpressed, and the like, so as to improve a metabolic flux j of a precursor substance tyrosine; tyrosine deaminase, 4-coumarate:CoA-ligase, chalcone synthase and chalcone isomerase are expressed heterogeneously, so as to realize de novo synthesis of naringenin. Finally, the yield of naringenin is further improved by high-efficiency expression of Sc4CL and HaCHS at multiple copy sites.

This invention relates to the field of pharmaceutical and chemical intermediates technology, and discloses a novel class of substituted phenylethyl-O-β-D-glucuronide compounds. These compounds are generated using substituted phenylethanol as a substrate and 1-fluoro-D-glucuronic acid as a glycosyl donor, catalyzed by β-glucuronyltransferase derived from *E. coli*. The process yield can reach over 95%, and the reaction conditions are mild and environmentally friendly. Substituted phenylethyl-O-β-D-glucuronide can be efficiently used for the determination of β-glucuronidase activity, and its applications are wide-ranging and reliable. The product can meet the needs of pharmaceutical, food, and other fields for β-glucuronidase activity control. It can be used for enzyme activity detection in the auxiliary diagnosis of clinical diseases, and also for enzyme quality control in fruit juice clarification processes in the food industry, drug precursor activation, and glycan structure analysis in the biopharmaceutical field. The product structure has been verified to be accurate by mass spectrometry and 1H NMR spectroscopy, and enzymatic hydrolysis experiments have confirmed its reliable application.

A tablet for extraction of a beverage, formed by cohesion of a dosed amount of a precursor substance in granular or powder form has a reference surface with one or more graphic recognition markings adapted to provide protection from abrasion of the precursor substance, and optionally a higher degree of cohesion, in a region where the one or more graphic recognition markings are formed compared to a region of the reference surface devoid of the graphic recognition markings. A method for producing a tablet for extraction of a beverage, the tablet being formed of a dosed amount of a precursor substance in granular or powder form, involves forming a tablet with self-supporting structure, and making graphic recognition markings on a reference surface of the tablet, adapted to provide protection from abrasion of the precursor substance in a region of the reference surface where the graphic recognition markings are formed.

The invention relates to an anti-alcoholism composition, a liquid preparation with an anti-alcoholism effect and a preparation method and application of the liquid preparation, and belongs to the technical field of physiology. The anti-alcohol composition comprises an NAD (nicotinamide adenine dinucleotide) precursor substance and amino acid, and the NAD precursor substance is one or more of nicotinamide, nicotinamide ribose, nicotinamide mononucleotide or nicotinic acid; and the amino acid is one or more of L-glutamine, L-serine or L-lysine. The special combination of the NAD precursor substance and the amino acid can synergistically accelerate ethanol metabolism, and the alcohol effect dispelling liquid preparation prepared on the basis of the alcohol effect dispelling liquid preparation is flexible in use time, controllable in component and outstanding in alcohol effect dispelling effect, and has very wide application prospects.

The invention discloses an aldehyde ketoreductase 1C3 selective inhibitor with a tricyclic structure and application of the aldehyde ketoreductase 1C3 selective inhibitor. The invention discloses a series of compounds with a structure as shown in a general formula I, and also discloses application of the compounds in cancer treatment. The inventor evaluates the efficacy of the compound represented by the general formula I in treatment of various cancers by taking an in-vitro anti-tumor cell experiment as a carrier, and finds that the compound has good in-vitro activity and can be used as a precursor substance for further development of a cancer treatment effect by inhibiting AKR1C3.

The invention belongs to the field of microorganisms and fermentation engineering, and discloses recombinant escherichia coli for producing valerolactam as well as a construction method and application of the recombinant escherichia coli. The method comprises the following steps: firstly, modularly optimizing the expression level of a heterologous gene and optimizing a whole-cell catalytic reaction system by using promoter engineering; then, the catabolism of pyruvic acid and the synthesis path of L-lysine are modified, and the supply of precursor substances is enhanced, so that the recombinant escherichia coli realizes de novo synthesis of the valerolactam, and the synthesis efficiency of the valerolactam is remarkably improved. Compared with the prior art, the invention not only provides two methods of whole-cell catalysis and de novo synthesis of the valerolactam, but also effectively avoids the problem of environmental pollution generated in the chemical synthesis process, embodies the concept of green synthesis, and ensures that the yield of the valerolactam reaches a higher level even only at a shake flask level. Important application prospects are provided for efficient synthesis of valerolactam.

A bag (10) for producing a foam-in-bag dunnage material comprises a closed edge portion (16a-c) and, in a non- sealed state of the bag, an open edge portion (16d), the closed and open edge portions (16a-d) delimiting an inner bag volume (22). The invention proposes that a bag structure of the bag (10) comprises a mixing chamber (24) which is adapted to receive foam precursor substances, which is arranged within the inner bag volume (22), which is at least partially and initially delimited against the remainder (28) of the inner bag volume (22), and which in the non-sealed state of the bag (10) is connected to the open edge portion (16d).

The application belongs to the technical field of homogeneous catalysis, and provides application of a ten-core 3d-4f supramolecular nanocage material in catalyzing a three-component aza-Darzens reaction. The application comprises the following steps: mixing an aldehyde compound, an amino benzene compound, ethyl diazoacetate, the ten-core 3d-4f supramolecular nanocage material and an organic solvent, and then performing a reaction to obtain a reaction product, namely completing the three-component aza-Darzens reaction. The ten-core 3d-4f supramolecular nanocage material is used as a catalyst to catalyze the three-component aza-Darzens reaction to realize synthesis of a drug precursor with biological activity, and the catalyst has high catalytic efficiency, the operation steps are simple, and the yield of the target product is also high.

The invention provides a phosphoketolase mutant, a related product of the phosphoketolase mutant and application of the phosphoketolase mutant in production of acetyl phosphate, acetyl coenzyme A and / or 3-hydracrylic acid. The phosphoketolase mutant provided by the invention has relatively high catalytic capability on hexanediose and pentose, and can catalyze hexanediose and pentose to be converted into acetyl phosphoric acid at relatively high efficiency, so that subsequent products acetyl coenzyme A and 3-hydracrylic acid are efficiently generated; therefore, the method has great application potential in production of acetyl coenzyme A and products (such as 3-hydracrylic acid) taking acetyl coenzyme A as a precursor substance.

The invention discloses a central targeting tacrine conjugate based on a transporter as well as a preparation method and application of the central targeting tacrine conjugate. The structures of the central targeting tacrine conjugate based on the transporter are shown in general formulas I and II. According to the invention, cholinesterase inhibitory activity, transport penetration experiment, cytotoxicity and blood brain distribution are taken as evaluation indexes, and the potential of the compound in treatment of Alzheimer's disease is systematically investigated. Experimental results show that the compound shows good in-vitro safety, remarkable cholinesterase inhibitory activity and excellent blood-brain barrier permeability, and can be further developed into a precursor substance for resisting Alzheimer's disease with central targeting.

The invention discloses a composition containing valsartan and fineglitazone and a preparation method of the composition, and relates to the technical field of pharmaceutical compositions.According to the composition, valsartan, fineglitazone, a curcumin phospholipid complex and L-arginine are scientifically proportioned, a three-dimensional kidney protection network is constructed, and the kidney protection effect is improved. Valsartan and fineglitazone cooperate to block excessive activation of RAAS, blood pressure is effectively reduced, glomerular hyperfiltration is relieved, aldosterone-mediated renal fibrosis and inflammatory response can be inhibited, on the basis, the curcumin phospholipid complex improves bioavailability of fat-soluble curcumin through a phospholipid carrier, and the bioavailability of fat-soluble curcumin is improved. The microencapsulated L-arginine can specifically enhance the activity of antioxidant enzymes in kidney tissues and relieve oxidative damage to renal tubular epithelial cells, and the microencapsulated L-arginine serves as an NO precursor substance, controls the slow release rate through an eudragit EPO coating, continuously supplements an NO synthetic substrate, repairs an NO signal channel of damaged vascular endothelial cells and reduces serum creatinine and urea nitrogen levels.

The present invention relates to the application of genes BldD, metK, and genC in regulating the production of gentamicin, and provides a method for increasing the yield of gentamicin biosynthesis by Micromonospora echinospora. The present invention studies and discovers that overexpressing the genC gene can increase the conversion of precursor substances, with the expectation of increasing the total metabolic flux of gentamicin; overexpressing the metK gene can improve the efficiency of transmethylation reaction, with the expectation of increasing the final yield of gentamicin; overexpressing BldD, and through shake-flask fermentation of this engineered strain, it is further discovered that the BldD gene can positively regulate the production of gentamicin and has an obvious impact on its morphology during the fermentation process. Through the above research on the regulatory factors in the process of gentamicin synthesis, the titer of gentamicin can be increased at the gene regulation level.

The application discloses a method for preparing a vortioxetine drug precursor by a mechanical grinding method catalyzed C-S coupling reaction. The technical scheme is as follows: 2,2'-diamino diphenyl disulfide and 2,4-dimethyl bromobenzene are used as raw materials, a C-S coupling reaction is carried out by using a Ni catalysis and a trace liquid assisted mechanical grinding method under a normal temperature and a solvent-free condition to prepare 2,4-dimethyl phenyl-2-piperazine phenyl sulfide, and the coupling product is obtained in a green and safe manner. The C-S coupling reaction is carried out by using the mechanical force method to prepare the vortioxetine drug precursor, the operation and treatment are simple, the raw materials are green and safe, the method is environment-friendly, a metal Ni is used for catalysis, the reaction condition is mild, and the reaction can be completed in 99 minutes.

This invention discloses a method for increasing the yield of acetylglucosamine in Bacillus subtilis. The method involves knocking out and verifying the key phosphatase YwpJ, which catalyzes the dephosphorylation of GlcNAc-6-P to generate GlcNAc. Overexpression of YwpJ reduces the excessive accumulation of intracellular phosphate sugars, eliminating the toxic effects of excessive phosphate sugars on cells and effectively secreting phosphate sugars extracellularly, thereby improving cell growth. Furthermore, knocking out the key genes murQ and nagBB in the GlcNAc synthesis precursor degradation pathway blocks the degradation of precursor substances, reduces carbon flux waste, and allows more carbon flux to be converted into products. Ultimately, the GlcNAc yield of the recombinant strain FMIP34 reached 26.1 g / L, an increase of 61.1%, and the GlcNAc conversion rate reached 0.483 g / g glucose.

A control system and method for a machine (1) for preparing and dispensing hot drinks by controlled infusion of a precursor substance in particulate or powder form based on identification and classification of dosage units (8) inserted in the machine (1). A control system and method are described for a machine (1) for preparing and dispensing hot drinks by controlled infusion of a precursor substance in the form of particles or powder arranged in a dosage unit (8), an automatic image recognition and processing unit (84) of the machine learning type is configured to classify a dose unit (8) received by the machine as one of a plurality of predetermined categories of dose units based on a set of training images of the dose unit taken in the learning step. The training image set of the dose unit comprises at least a plurality of primary images of the dose unit (8) and a plurality of composite images obtained by changing the plurality of primary images, the primary images comprising respective predetermined graphical identification marks (70, 72) on a reference surface of the dose unit (8) indicating a corresponding category of the dose unit.